Further Characterization of the Guinea Pig Cerebral Cortex Idazoxan Receptor: Solubilization, Distinction from the Imidazole Site, and Demonstration of Cirazoline as an Idazoxan Receptor‐Selective Drug
- 1 July 1990
- journal article
- research article
- Published by Wiley in Journal of Neurochemistry
- Vol. 55 (1) , 192-203
- https://doi.org/10.1111/j.1471-4159.1990.tb08838.x
Abstract
We have demonstrated previously that [3H]idazoxan, besides being able to bind to α2-adrenergic receptors, may also bind to a nonadrenergic idazoxan-receptor site with high affinity. The idazoxan receptor is tightly bound to cellular membranes, and we have now developed a method to solubilize it from the guinea pig cerebral cortex by using the detergent 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). The CHAPS-solubilized receptor retains its binding properties for drugs: the membrane-bound, as well as the solubilized, idazcxan receptor shows high affinities for a number of imidazolines (cirazoline, idazoxan, tolazoline, naphazoline, tramazoline, clonidine, and oxymetazoline), some imidazoles (medetomidine, detomidine), and guanfacine. By contrast, catecholamines (adrenaline, noradrenaline, isoprenaline, and dopamine) and a number of other neurotransmitters and neuromodulators (serotonin, histamine, glutamic acid, γ-aminobutyric acid, glycine, and adenosine) show negligible affinities for the idazoxan receptor. Moreover, the idazoxan receptor shows grossly different binding properties for histamine, cimetidine, and imidazole-4-acetic acid compared to what has been described for the nonadrenergic imidazole site labeled by p-[3H]aminoclonidine, indicating that the two receptor sites are distinct. Radioligand binding data further indicate that cirazoline is an idazoxan receptor-selective drug (KD= 1 nM) showing a 50–210-fold selectivity for binding to the idazoxan receptor when compared to α2-adrenergic receptors and an about 500-fold selectivity when compared to α1-adrenergic receptors. We have also reviewed the literature for possible nonadrenergic actions of idazoxan and cirazoline, and we suggest that idazoxan receptors might be involved in the control of prolactin release from the pituitary.Keywords
This publication has 30 references indexed in Scilit:
- Postischemic Administration of Idazoxan, an α-2 Adrenergic Receptor Antagonist, Decreases Neuronal Damage in the Rat BrainJournal of Cerebral Blood Flow & Metabolism, 1989
- Prolactin (PRL) release-inhibiting properties of the α2 adrenergic receptor antagonist Idazoxan: Comparison with yohimbineLife Sciences, 1989
- High Affinity Binding of Idazoxan to a Non‐Catecholaminergic Binding Site in the Central Nervous System: Description of a Putative Idazoxan‐ReceptorBasic & Clinical Pharmacology & Toxicology, 1989
- Guanine Nucleotides Regulates Both Agonist and Antagonist Binding to Cod Brain α1-AdrenoceptorsActa Pharmacologica et Toxicologica, 1986
- Solubilization and Characterization of Rat Brain ?2-Adrenergic ReceptorJournal of Neurochemistry, 1985
- Isolation and partial purification of a clonidine‐displacing endogenous brain substanceEuropean Journal of Biochemistry, 1984
- Solubilization of brain alpha-2 adrenoceptor with a zwitterionic detergent: Preservation of agonist binding and its sensitivity to GTPBiochemical and Biophysical Research Communications, 1984
- Solubilization of Active Brain α1-Adrenoceptors by a Zwitterionic DetergentJournal of Neurochemistry, 1983
- Pharmacology of B‐HT 920 in some Isolated Smooth Muscles of the Guinea‐pigActa Pharmacologica et Toxicologica, 1982
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973